Welcome to our dedicated page for Albertsons Companies SEC filings (Ticker: ACI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Albertsons Companies, Inc. filings document material events for a public food and drug retailer, including furnished operating results, Regulation FD disclosures, board changes, and financing transactions. Recent 8-Ks cover quarterly and annual financial results, opioid-related claim disclosures, director appointments and resignations, and senior note offerings or refinancings involving the company and subsidiary co-issuers such as Safeway Inc., New Albertsons L.P., Albertson's LLC and Albertsons Safeway LLC.
The filing record also describes capital-structure terms for senior notes due 2031, 2032 and 2034, use of proceeds for debt refinancing and revolver repayment, stockholder-agreement governance matters, Class A common stock ownership references, exhibits, and Inline XBRL cover-page data.
Withers Michael reported acquisition or exercise transactions in this Form 4 filing.
Albertsons Companies executive Michael Withers received new equity awards in the form of restricted stock units. On April 16, 2026, he was granted performance-based restricted stock units that represent a target of 15,781 shares of Class A common stock, which vest on February 24, 2029 if fiscal 2026–2028 performance goals are achieved and certified and he remains in service through that date. He was also granted 47,343 time-based restricted stock units, each convertible into one share of Class A common stock, vesting in three equal installments on February 27, 2027, February 26, 2028, and February 24, 2029, subject to continued employment. These are compensation grants at no cash purchase price, not open-market stock purchases or sales.
Pinkham Allison Suzanne reported acquisition or exercise transactions in this Form 4 filing.
Albertsons Companies EVP and Chief HR Officer Allison Suzanne Pinkham received new equity awards in the form of restricted stock units. On April 16, 2026 she was granted several performance-based restricted stock unit (PBRSU) awards tied to Class A common stock, each unit representing one future share.
The PBRSUs vest on February 24, 2029, but only if performance goals for fiscal years 2026, 2027, and 2028 are achieved, the Compensation Committee certifies results, and she remains in service through that certification date. The reported PBRSU amounts are target levels; the actual number earned will depend on performance.
She was also granted time-based restricted stock units (TBRSUs) covering Class A common stock. These TBRSUs vest in three equal installments on February 27, 2027, February 26, 2028, and February 24, 2029, provided she remains continuously employed through each vesting date. No open-market purchases or sales were reported; these are compensation-related grants.
Larson Robert Bruce reported acquisition or exercise transactions in this Form 4 filing.
Albertsons Companies, Inc. reported that SVP & Chief Accounting Officer Robert Bruce Larson received equity awards in the form of restricted stock units. He was granted 22,908 time-based restricted stock units tied to Class A common stock and three performance-based restricted stock unit awards of 7,636 units each, also tied to Class A common stock.
The time-based units vest in three equal installments on February 27, 2027, February 26, 2028, and February 24, 2029, if he remains employed through each date. The performance-based units are scheduled to vest on February 24, 2029, depending on achievement of performance goals for fiscal years 2026, 2027, and 2028 and certification by the Compensation Committee.
Albertsons Companies reported fiscal 2025 results showing modest sales growth but a large legal charge. Net sales reached $83.2 billion, with identical sales up 2.0%. For the year, net income was $217.4 million, while Adjusted EBITDA was $3.90 billion.
In the fourth quarter, net sales were $20.3 billion and the company posted a net loss of $480.8 million, driven by a $773.8 million pre-tax charge related to an opioid settlement framework. Excluding this and other adjustments, adjusted net income was $251.7 million and Adjusted EBITDA was $903.4 million.
Albertsons reached a $774 million opioid settlement framework payable over nine years, with an estimated after-tax net present value of $482 million, and recorded a related after-tax charge of about $600 million. The Board raised the quarterly dividend 13% to $0.17 per share and increased remaining share repurchase authorization to $2.0 billion. For fiscal 2026, the company guides to identical sales growth of 0.0%–1.0%, Adjusted EBITDA of $3.85–$3.93 billion, and adjusted net income per share of $2.22–$2.32.
Albertsons Companies reported fiscal 2025 results showing modest sales growth but a large legal charge. Net sales reached $83.2 billion, with identical sales up 2.0%. For the year, net income was $217.4 million, while Adjusted EBITDA was $3.90 billion.
In the fourth quarter, net sales were $20.3 billion and the company posted a net loss of $480.8 million, driven by a $773.8 million pre-tax charge related to an opioid settlement framework. Excluding this and other adjustments, adjusted net income was $251.7 million and Adjusted EBITDA was $903.4 million.
Albertsons reached a $774 million opioid settlement framework payable over nine years, with an estimated after-tax net present value of $482 million, and recorded a related after-tax charge of about $600 million. The Board raised the quarterly dividend 13% to $0.17 per share and increased remaining share repurchase authorization to $2.0 billion. For fiscal 2026, the company guides to identical sales growth of 0.0%–1.0%, Adjusted EBITDA of $3.85–$3.93 billion, and adjusted net income per share of $2.22–$2.32.
Albertsons Companies reported fiscal 2025 results showing modest sales growth but a large legal charge. Net sales reached $83.2 billion, with identical sales up 2.0%. For the year, net income was $217.4 million, while Adjusted EBITDA was $3.90 billion.
In the fourth quarter, net sales were $20.3 billion and the company posted a net loss of $480.8 million, driven by a $773.8 million pre-tax charge related to an opioid settlement framework. Excluding this and other adjustments, adjusted net income was $251.7 million and Adjusted EBITDA was $903.4 million.
Albertsons reached a $774 million opioid settlement framework payable over nine years, with an estimated after-tax net present value of $482 million, and recorded a related after-tax charge of about $600 million. The Board raised the quarterly dividend 13% to $0.17 per share and increased remaining share repurchase authorization to $2.0 billion. For fiscal 2026, the company guides to identical sales growth of 0.0%–1.0%, Adjusted EBITDA of $3.85–$3.93 billion, and adjusted net income per share of $2.22–$2.32.
Albertsons Companies EVP Thomas M. Moriarty exercised performance-based restricted stock units into 3,264 shares of Class A common stock on December 1, 2025, through three derivative conversions of 1,296, 941 and 1,027 units. These units relate to awards granted in 2023 and 2024 that were earned in February 2026 and February 2027. Following the transactions, he directly holds 48,030 shares, with an additional 45,725 shares held indirectly through a family trust, for which he disclaims beneficial ownership of 22,862 shares.
Albertsons Cos Inc — The Vanguard Group filed Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership of Common Stock as 0 shares (0%). The filing states that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries will report ownership separately in reliance on SEC Release No. 34-39538.
Albertsons Companies, Inc. executive Michael Withers, EVP Retail Operations West, reported a Form 4 transaction involving 6,403 shares of Class A common stock on March 11, 2026. The event is coded as an "other acquisition or disposition" related to restructuring, with no price per share reported, and leaves him holding 13,410 shares directly.
Albertsons Companies director Sarah Mensah reported acquiring shares of Class A common stock through an equity award vesting. On February 28, 2026, a restricted stock unit award fully vested, and on March 2, 2026 she received 9,471 shares. After this transaction, she directly holds 17,669 shares of Class A common stock. This was an exercise or conversion of a derivative security rather than an open-market purchase.
Albertsons Companies director Alan H. Schumacher reported his indirect holdings of Class A common stock. The filing shows that 75,539 shares are held through The Alan H. Schumacher Declaration of Trust dated October 19, 2001. As trustee, Schumacher is deemed to have voting and dispositive power over these trust-held shares. This amendment functions as an update of indirect ownership rather than a new market transaction, giving a clearer picture of how his Albertsons stake is structured.
Albertsons Companies director Brian Kevin Turner acquired 9,471 shares of Class A common stock through an option or similar derivative exercise. The shares relate to restricted stock units, each representing one share, from an award that fully vested on February 28, 2026. Following this transaction, Turner directly holds 161,219 shares, reflecting a routine compensation-related equity increase rather than an open-market purchase or sale.